Biotechnology VALUE FUND L P, 10% Owner at Nivalis Therapeutics, Inc. (NVLS), bought 103,823 shares at $2.30 ($239K) on 2017-05-17, disclosed to the SEC on 2017-05-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.30 | 5,510 | $13K | 5.3% |
| 2 | $2.30 | 6,897 | $16K | 6.6% |
| 3 | $2.30 | 24,965 | $57K | 24.0% |
| 4 | $2.30 | 24,965 | $57K | 24.0% |
| 5 | $2.30 | 2,909 | $7K | 2.8% |
| 6 | $2.30 | 10,541 |
| $24K |
| 10.2% |
| 7 | $2.30 | 16,436 | $38K | 15.8% |
| 8 | $2.30 | 1,124 | $3K | 1.1% |
| 9 | $2.30 | 4,223 | $10K | 4.1% |
| 10 | $2.30 | 6,253 | $14K | 6.0% |
| Total | $2.30 avg | 103,823 | $239K | 100% |
| Filing → |
| KYMR | BUY | 2022-05-24 | $141K | — | Filing → |
| OLMA | BUY | 2021-12-02 | $13.9M | — | Filing → |
| KYMR | BUY | 2021-07-06 | $25.6M | — | Filing → |